GLP-1 RA use was associated with reduced alcohol intake, relapse rates, and incidence of alcohol-related diagnoses, especially in individuals with type 2 diabetes or obesity prescribed Semaglutide or liraglutide. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.